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Objectives: In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with 
diabetes mellitus treated with Orsiro sirolimus-eluting stent (O-SES; Biotronik, Bülach, 
Switzerland) or Nobori biolimus-eluting stent (N-BES; Terumo, Tokyo, Japan) were compared.  
Background: Diabetes is associated with increased risk of target lesion failure (TLF) after 
percutaneous coronary intervention.  
Methods: In total 2,525 patients were randomized to stent implantation with O-SES (n=1,261, 
diabetes: n=236) or N-BES (n=1,264, diabetes: n=235). The primary endpoint, TLF, was a 
composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion 
revascularization (TLR) within 2 years.  
Results: At 2-year, TLF did not differ between O-SES versus N-BES in diabetic (9.3% versus 
9.4%; RR 0.98, 95% CI 0.54-1.78) patients. The individual components of the primary endpoint did 
not differ among stent type. In diabetics, cardiac death occurred in 3% of O-SES-treated and in 
3.8% of N-BES-treated patients (RR 0.77, 95% CI 0.29-2.08), MI occurred in 3.0% of O-SES-
treated and in 3.8% of N-BES-treated patients (RR 0.76, 95% CI 0.28-2.06) and TLR occurred in 
5,5% of O-SES-treated and in 6.0% of N-BES-treated patients (RR 0.91, 95% CI 0.43-1.95).  
Conclusion: TLF did not differ between O-SES and N-BES treated diabetic patients. 
 








   The presence of diabetes mellitus has been associated with higher risk of restenosis and major 
cardiovascular events after percutaneous coronary intervention (PCI) [1]. New-generation drug-
eluting stents (DES) are recommended for the treatment of diabetic patients undergoing PCI 
because of a lower risk of repeated revascularization compared with bare-metal stents and early 
generation DES [2]. Among available new-generation DES, the thin-strut durable polymer 
everolimus-eluting stent (EES) has emerged as the currently most effective and safest durable 
polymer stent in this high-risk group [3]. However, long-term persistence of some durable polymers 
may create a chronic local inflammatory response, disturb vascular healing, and be responsible for 
the late stent thrombosis and delayed restenosis [4]. In order to improve biocompatibility and long-
term safety, the new biodegradable polymer DESs have been designed to reduce chronic local 
inflammation by degradation of the polymer-coating after complete elution of the anti-proliferative 
drug. Compared with durable polymer EES, the biodegradable polymer Nobori biolimus-eluting 
stent (N-BES) showed similar long-term efficacy and safety in this specific population of diabetic 
patients [5]. In a substudy of the “ultrathin strut biodegradable polymer sirolimus-eluting stent 
versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization 
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(BIOSCIENCE) trial”, the clinical outcomes among diabetic patients treated with biodegradable 
polymer Orsiro sirolimus-eluting stent (O-SES) or durable polymer EES were comparable at 1 year 
[6]. The aim of the present study (a substudy of SORT OUT VII) was to compare long-term 
efficacy and safety of two biodegradable polymer stents, O-SES versus N-BES, in patients with and 
without diabetes mellitus.  
  
 
MATERIALS AND METHODS  
 
   SORT OUT VII [7] is a randomized, multicenter, all-comer, 2-arm, noninferiority trial comparing 
O-SES to N-BES in treating atherosclerotic coronary artery lesions. A detailed study protocol was 
provided in the main publication [8].  
 
Inclusion Criteria 
   Patients were eligible if they were ≥18 years old, had chronic stable coronary artery disease or 
acute coronary syndromes, and ≥1 coronary lesion with >50% diameter stenosis. If multiple lesions 
were treated, the allocated study stent was used in all lesions. There were no restrictions in number 
of treated lesions, number of treated vessels, or lesion length.  
 
Exclusion Criteria  
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   Patients were excluded from the study if life expectancy of <1year; allergy to aspirin, clopidogrel, 
prasugrel, ticagrelor, sirolimus, or biolimus; participation in another randomized stent trial; or 
inability to provide written informed consent.  
 
Randomization and Management 
   Patients were enrolled by the investigators and randomly allocated to treatment groups after 
diagnostic coronary angiography and before PCI. Block randomization by center (permuted blocks 
of random sizes (7/9/11)) was used to assign patients in a 1:1 ratio to receive the biodegradable 
polymer O-SES (Orsiro; Biotronik, Bülach, Switzerland) or the biodegradable polymer N-BES 
(Nobori, Terumo, Tokyo, Japan). Randomization was stratified by presence/absence of diabetes. An 
independent organization computer generated the allocation sequence, stratified by gender and 
presence of diabetes. Patients were assigned to treatment through a web-based randomization and 
electronic case record form software (TrialPartner). Stents were implanted according to standard 
techniques. Direct stenting without previous balloon dilatation was allowed. Full lesion coverage 
was attempted by implanting ≥1 stents. Before implantation, patients were treated with 
acetylsalicylic acid (loading dose of 300mg) and loaded with either clopidogrel, 600mg; ticagrelor, 
180mg; or prasugrel, 60mg. Combination of dual antiplatelet therapy was left to the discretion of 
the participating center, whereas the duration of dual antiplatelet therapy was recommended for 12 
months. Unfractionated heparin dose (5,000 IE or 70-100IU/kg) was administered before the 
procedure. Glycoprotein IIb/IIIa inhibitors or bivalirudin were used at the operator’s discretion. 
    
Endpoints 
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   Definitions of endpoints were provided in the main publication [8]. The primary endpoint “target 
lesion failure” (TLF) of this substudy was a composite of cardiac death, myocardial infarction (MI) 
(not related to other than index lesion) or clinically indicated target lesion revascularization (TLR) 
within 24 months of stent implantation. Individual components of the primary endpoint comprised 
the secondary endpoints: cardiac death; MI; clinically indicated TLR; all death (cardiac and 
noncardiac) and target vessel revascularization (TVR); definite, probable, and overall stent 
thrombosis according to the Academic Research Consortium definition [9]; and a patient-related 
composite endpoint (all death, all MI, or any revascularization).  
 
Data Collection 
   Clinically driven event detection was used to avoid study-induced re-interventions. Data on 
mortality, hospital admission, coronary angiography, repeated PCI, and coronary bypass surgery 
were obtained for all randomly selected patients from the following national registries: Civil 
Registration System; Western Denmark Heart Registry [10]; Danish National Registry of Patients 
[11], which maintains records on all hospitalizations in Denmark; and Danish Registry of Causes of 
Death [12]. An independent event committee, which was blinded to treatment group assignment 
during the adjudication process, reviewed all endpoints and source documents to adjudicate causes 
of death, reasons for hospitalization, and diagnosis of MI. In addition, the cine films were reviewed 
independently by two experienced PCI-operators to classify stent thrombosis and TVR (with PCI or 
coronary artery bypass grafting). The Danish National Health Service provides universal tax-
supported health care, guaranteeing residents free access to general practitioners and hospitals. The 
Danish Civil Registration System has kept electronic records on gender, birthdate, residence, 
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emigration date, and vital status changes since 1968 [13] with daily updates. A unique 10-digit civil 
registration number is assigned to all residents at birth and upon immigration and is used in all 
registries, which allows accurate record linkage between registries. The Civil Registration System 
provided vital status data for our study participants, which reduced the probability of loss to follow-
up. To capture co-morbidity, we used the Danish National Registry of Patients to obtain data on all 
hospital diagnoses in study patients from 1977 until the implantation date [11]. We then computed 
Charlson Comorbidity Index scores, which cover 19 major disease categories including heart 
failure, cerebrovascular diseases, and cancer [14]. 
 
Statistical Analysis 
   Distributions of continuous variables were compared between study groups using 2-sample t test 
(or Cochran test for cases of unequal variance) or Mann-Whitney U Test depending on whether the 
data followed a normal distribution. Distributions of categorical variables were compared using chi-
square test. In analyses of every endpoint, follow-up continued until the date of an endpoint event, 
death, emigration, 24 months after stent implantation, or study end - whichever came first. Survival 
curves were constructed based on cumulated incidences, accounting for death as a competing risk 
[15]. Patients who received the N-BES were used as the reference group for overall and subgroup 
analyses. We calculated rate ratios (RR) for TLF at 24-month follow-up for prespecified patient 
subgroups (based on baseline demographic and clinical characteristics). To improve the precision of 
risk estimates, we used the change-in-estimate method, which entailed retaining variables that 
changed relative risk estimates for an outcome by >10% [16]. Number of variables included in the 
final regression models varied from 0 to 1. The intention-to-treat principle was used in all analyses.  
This article is protected by copyright. All rights reserved.
A two-sided p value of less than 0.05 indicated statistical significance. We calculated RR by 
modified Poisson regression analysis with a sandwich error estimation [17] to assess whether 
difference detected at baseline had any effect on the result. Analyses were conducted using SAS 9.4 
(SAS Institute, Cary, North Carolina). This trial is registered with ClinicalTrials.gov 





   Between November 2012 and February 2014, 2,525 patients were randomly assigned to receive 
either the biodegradable polymer O-SES (1261 patients (1590 lesions)) or the biodegradable 
polymer N-BES (1264 patients (1588 lesions)). In total, 471 patients had diabetes, of whom 236 
patients received O-SES and 235 patients received N-BES. Three patients were lost to follow-up 
(on day 6, 81 and 610) because of emigration. Complete follow-up data were available for 2,522 
patients (99.9%) for all type of events.  
 
Patient Characteristics 
   Baseline patient characteristics for diabetics are summarized in Table I and did not differ 
significantly between the patient groups except for age, which was significantly higher in diabetic 
patients, who received the biodegradable polymer O-SES compared to the N-BES (67.3 ± 10.6 
years vs. 65.0 ± 10.0 years, p=0.02).  
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Lesion and procedure characteristics  
   Lesion and procedure characteristics did not differ significantly between the patients treated with 
O-SES and N-BES in the diabetic subgroup (Table II).  
 
Outcome    
   Composite endpoint TLF and individual components of the primary endpoint are presented in 
Table III. At 24-month follow-up, in patients with diabetes, the occurrence of TLF did not differ 
significantly in patients treated with O-SESs compared to patients treated with N-BESs (n=22, 
9.3%, vs. n=22, 9.4%, RR 0.98, 95% CI 0.54 to 1.78, p=0.94) (Figure 1 and Table III). There were 
also no differences in the individual components of the primary endpoint in diabetics treated with 
O-SESs versus N-BESs (Table III, Figure 2-4). Differences by type of stent were driven mainly by 
numerically lower rates of definite and definite/probable stent thrombosis in the O-SES group 
(Table III and Figure 5). 
   Of the 471 patients with diabetes mellitus, 137 (29.1%) were treated with insulin. There was no 
difference in TLF in insulin-treated diabetic patients treated with O-SESs versus N-BESs (n=5, 
10.4%, vs. n=7, 10.4%, RR 0.63, 95% CI 0.20 to 2.04, p=0.44) or in noninsulin treated diabetic 
patients treated with O-SESs versus N-BESs (n=17, 10.2%, vs. n=15, 8.9%, RR 1.15, 95% CI 0.57 
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   The present SORT OUT VII subgroup analyses provide the first clinical head-to-head comparison 
of two third-generation DES with biodegradable polymers, the O-SES versus the N-BES, in patients 
with and without diabetes mellitus. Our trial showed no significant difference between stent type for 
diabetic patients overall.  
   Patients with diabetes have a higher risk of restenosis after stenting, making DESs preferable to 
bare-metal stents in this patient population. First-generation DESs decreased restenosis rates 
significantly compared to bare-metal stents, especially in patients with diabetes [18-22]. 
Randomized studies comparing the first two DESs found that the sirolimus-eluting stent compared 
to the paclitaxel-eluting stent was associated with less TLR in patients with diabetes [18-20, 22]. 
Efficacy and safety of second-generation EES and zotarolimus-eluting stents versus first-generation 
DESs in patients with diabetes were evaluated in a meta-analysis of randomized trials [23]. A total 
of 18 trials comprising of 8095 patients were included. Compared to first-generation DES, EES 
significantly decreased major adverse cardiac events by 18%, MI by 43%, and stent thrombosis by 
46% in patients with diabetes. Moreover, EES showed a trend towards a reduction in rates of TLR 
and TVR (p=0.05). Zotarolimus-eluting stent was associated with an 89% increased risk of TLR 
compared to first-generation DES [23]. 
   Current evidence supports the use of durable polymer EES in patients with diabetes mellitus 
undergoing PCI. However, diabetes mellitus attenuates the antirestenotic effects of DES and the 
risk of adverse events after PCI is higher for diabetics compared with patients without diabetes 
mellitus.  
   Biodegradable polymer DES was conceived to overcome the safety issues of early generation 
durable polymer DES. Polymer remnants within the arterial wall may impair vascular healing and 
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be responsible for long term adverse events, such as late stent thrombosis and delayed restenosis 
[24]. The pooled analysis of 3 randomized clinical trials (ISAR-TEST 3, ISAR-TEST 4 and 
LEADERS), which included 1094 patients with diabetes in the analysis, compared the first-
generation biodegradable polymer DES with durable polymer DES. In patients with diabetes, 
biodegradable polymer DES showed comparable clinical outcomes compared with first generation 
durable polymer DES and a favorable safety profile with significantly lower rates of stent 
thrombosis at 4 years of follow-up [24]. 
   However, a non-randomized study comparing the 20-month efficacy and safety of the 
biodegradable polymer N-BES and the reference durable polymer EES in diabetic patients showed 
no significant differences [5]. Compared to our results, the mortality rate in the N-BES group for 
diabetic patients was lower. This is probably related to differences in the indications for PCI (more 
patients with ST-segment elevation myocardial infarction and Non-ST-segment elevation 
myocardial infarction in our study: 48.5% vs. 23%), comorbidity or patient selection [5].  
   The geometry of newer biodegradable polymer DES has been improved with a significant 
reduction of strut thickness. As compared to N-BES, which was the first DES with a biodegradable 
polymer, the newer O-SES has significantly thinner stent struts (60-80 µm compared to the 120 µm 
for the N-BES). Thin stent struts have been associated with less wall shear and thrombogenicity 
[25], which may be an explanation for the numerically lower rates of definite and definite/probable 
stent thrombosis in diabetic and nondiabetic patients treated with the O-SES. 
   The first subgroup analysis of the randomized “ultrathin strut biodegradable polymer sirolimus-
eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary 
revascularization (BIOSCIENCE) trial” looked at the clinical outcome according to diabetic status 
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in patients treated with O-SES versus the durable polymer EES [6]. Among 2119 patients enrolled, 
486 (22.9%) had diabetes mellitus. Overall, diabetic patients experienced a significantly higher risk 
of TLF compared with nondiabetic patients (10.1% vs. 5.7%, p=0.001). No significant differences 
were found for TLF and stent thrombosis among patients with diabetes mellitus allocated to the 
biodegradable polymer O-SES or the durable polymer EES group at 1 year. The TLF and the risk of 
definite or probable stent thrombosis for the O-SES was lower in the SORT OUT VII diabetes 
substudy compared to the BIOSCIENCE trial diabetes substudy at 1 year (TLF 4.7% vs. 10.9%; 
definite/probable stent thrombosis 1.3% vs. 4.0%). This difference can be explained partly by 
procedure-related MI, which was not part of the primary endpoint in the SORT OUT VII trial, and 




   The present analysis has some limitations. First, current findings are limited to 2-year follow-up 
whereas potential differences between the compared stents could emerge later. Second, SORT OUT 
VII was not powered for detection of differences among subgroups and subgroup analysis should 
consequently be considered as hypothesis-generating. Third, it should be noted that N-BES is not 
commercially available in a broad majority of countries anymore. However, our study provides 
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   The SORT OUT VII diabetes substudy showed that there was no difference between the 
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Figure 1. Time-to-event curve for the composite endpoint target lesion failure (TLF) at 24 months 
of follow up in diabetic patients. 
 
Figure 2. Time-to-event curve for cardiac death at 24 months of follow-up in diabetic patients. 
 
Figure 3. Time-to-event curve for myocardial infarction (MI) at 24 months of follow-up in diabetic 
patients. 
 
Figure 4. Time-to-event curve for target lesion revascularization (TLR) at 24 months of follow-up 
in diabetic patients. 
 
Figure 5. Time-to-event curve for the incidence of definite stent thrombosis at 24 months of follow-
up in diabetic patients. 
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